LNAI
Lunai Bioworks Inc.
NASDAQ · Healthcare · Biotechnology · US
$2.39
+1.70%Year over year
Reported trailing growth
- Revenue
- —
- EBITDA
- -29.1%
- EBIT
- +91.3%
- EPS
- —
- Free cash flow
- +38.1%
- Operating cash flow
- +38.0%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- —
- EBITDA
- —
- EBIT
- +77.3%
- Net income
- —
- EPS
- -18.5%
- Free cash flow
- +28.7%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026